BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Barbara Ann Karmanos Cancer Institute Researchers Identify Pathway for Treatment of Malignant Pleural Mesothelioma


4/17/2007 10:45:47 AM

DETROIT, April 17 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute today announced significant scientific findings that could lead to better treatment and therapies for cancer patients suffering from malignant pleural mesothelioma.

Karmanos scientists presented their research at the American Association of Cancer Research (AACR) annual meeting in Los Angeles, CA.

"We are getting closer and closer to making an impact on this insidious disease," said Anil Wali, Ph.D., an associate professor with Karmanos who led a group of cross-collaborative researchers in studying the ubiquitin-proteasome proteolytic (UPP) pathway regulatory proteins.

Their study demonstrated that protein ubiquitination and degradation are critical players in the spread of mesothelioma. After studying 241 genes involved in the UPP pathway, Wali's group determined 33 genes were differentially expressed among epithelioid and biphasic histotypes.

"We have already reported earlier detection biomarkers that can be utilized in assessing the high risk groups of patients," Dr. Wali said. "Now, if we can develop a therapy to target this pathway, we will be one step closer to halting this disease."

Malignant pleural mesothelioma is an aggressive, asbestos-related thoracic cancer affecting about 3,000 new patients in the United States annually. Despite advances in cancer treatment, the average survival rate remains low and the majority of patients die within two years of diagnosis. Currently there is no cure.

The Karmanos Cancer Institute has a long history of mesothelioma education and treatment. In 2004, the Institute joined with Wayne State University's Center for Occupational and Environmental Medicine to create the National Center for Vermiculite and Asbestos Related Cancers.

It addresses the need for early diagnosis and aggressive treatment for those afflicted with asbestos-related diseases. John C. Ruckdeschel, M.D., president and chief executive officer of KCI, co-directs the center in conjunction with Michael R. Harbut, M.D., M.P.H., F.C.C.P., an expert in the diagnosis and treatment of environmental and workplace diseases. Dr. Ruckdeschel, an internationally recognized figure in both lung cancer research and treatment, contributed to the research and authorship of today's presentation.

This study received funding from the Environmental Protection Agency (EPA) and the Center for Disease Control (CDC).

Based in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer. The Institute is one of 39 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D. is the Institute's president and CEO.

Barbara Ann Karmanos Cancer Institute

CONTACT: Courtney McCrimmon, +1-412-225-6899; or Linda Remington,+1-313-576-8614, both of Barbara Ann Karmanos Cancer Institute


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->